Cargando…
Congenital sacrococcygeal PNET and chemotherapy
We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523479/ https://www.ncbi.nlm.nih.gov/pubmed/23248428 http://dx.doi.org/10.4103/0971-5851.103151 |
_version_ | 1782253211019640832 |
---|---|
author | Hawkes, Colin Patrick Betts, David R. O’Brien, John O’Sullivan, Maureen J. Capra, Michael |
author_facet | Hawkes, Colin Patrick Betts, David R. O’Brien, John O’Sullivan, Maureen J. Capra, Michael |
author_sort | Hawkes, Colin Patrick |
collection | PubMed |
description | We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant “induction” chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily × 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of “maintenance” chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment. |
format | Online Article Text |
id | pubmed-3523479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-35234792012-12-17 Congenital sacrococcygeal PNET and chemotherapy Hawkes, Colin Patrick Betts, David R. O’Brien, John O’Sullivan, Maureen J. Capra, Michael Indian J Med Paediatr Oncol Case Report We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant “induction” chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily × 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of “maintenance” chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3523479/ /pubmed/23248428 http://dx.doi.org/10.4103/0971-5851.103151 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Hawkes, Colin Patrick Betts, David R. O’Brien, John O’Sullivan, Maureen J. Capra, Michael Congenital sacrococcygeal PNET and chemotherapy |
title | Congenital sacrococcygeal PNET and chemotherapy |
title_full | Congenital sacrococcygeal PNET and chemotherapy |
title_fullStr | Congenital sacrococcygeal PNET and chemotherapy |
title_full_unstemmed | Congenital sacrococcygeal PNET and chemotherapy |
title_short | Congenital sacrococcygeal PNET and chemotherapy |
title_sort | congenital sacrococcygeal pnet and chemotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523479/ https://www.ncbi.nlm.nih.gov/pubmed/23248428 http://dx.doi.org/10.4103/0971-5851.103151 |
work_keys_str_mv | AT hawkescolinpatrick congenitalsacrococcygealpnetandchemotherapy AT bettsdavidr congenitalsacrococcygealpnetandchemotherapy AT obrienjohn congenitalsacrococcygealpnetandchemotherapy AT osullivanmaureenj congenitalsacrococcygealpnetandchemotherapy AT capramichael congenitalsacrococcygealpnetandchemotherapy |